Nuclear factor-KB (NF-KB) activation promotes cell survival and growth. Reports show that chemotherapeutic agents and cytokines that are used for cancer therapy activate NF-KB expression in tumor cells and its suppression enhanced the antitumor activity. We hypothesized that adenovirus-mediated overexpression of melanoma differentiation-associated gene-7/interleukin-24 (Admda7/IL-24) induces NF-KB expression and that inhibition of this expression results in enhanced tumor cell killing.
Introduction
Nuclear factor-nB (NF-nB), which is activated after signaldependent phosphorylation and degradation of the inhibitor of nBa (InBa), has been shown to promote cell survival and growth (1, 2) . The activation of NF-nB in tumor cells after treatment with chemotherapeutic drugs, radiation, cytokines, and stress-inducing agents, such as free radicals, has been previously reported (3 -8) . However, these tumor cells undergo cell death over time, which indicates that NF-nB activation occurs as a protective mechanism to resist cell death. When the death signal overcomes the threshold of the cell survival signal, the cells undergo cell death or apoptosis (9, 10) . This suggests the novel paradigm that decreasing the cell survival threshold provided by NF-nB expression increases the sensitivity of cancer cells to chemotherapeutic drugs. In fact, NF-nB inhibition in cancer cells has been shown to potentiate the chemotherapeutic response (11, 12) . NF-nB inhibition has also been shown to enhance the radiosensitivity of human colon cancer cells (13) . Further, Sumitomo et al. (14) showed that cytokineproducing bladder cancer cells undergo apoptosis when NF-nB activation is suppressed by overexpressed InBa. These results show that NF-nB is activated in tumor cells by several mechanisms and that its inhibition enhances treatment-induced cell death.
The melanoma differentiation-associated gene-7/interleukin-24 (mda7/IL-24) gene is a novel tumor-suppressing cytokine gene that belongs to the interleukin-10 cytokine family (15, 16) . We and others previously showed that adenovirus-mediated overexpression of mda7 (Ad-mda7) selectively induces apoptosis in various human tumor cell lines, with no effect on normal cells (17 -21) . In a more recent study, we showed that Ad-mda7 treatment in combination with administration of sulindac, a nonsteroidal anti-inflammatory drug, enhanced lung tumor cell killing (22) . Similarly, the treatment of human breast cancer cells with Ad-mda7 and celecoxib, a cyclooxygenase-2 inhibitor, resulted in synergistic cell killing (23) . Although enhanced tumor cell killing after treatment with Ad-mda7 and sulindac or celecoxib was shown in these studies, the underlying molecular mechanism was not described. A separate study showed that mda7 enhanced tumor necrosis factor-a -mediated NF-nB activation in human 293 kidney cells and suppressed tumor necrosis factor-a -mediated apoptosis (24) .
We therefore hypothesized that Ad-mda7 induces NF-nB activation in tumor cells and that inhibition of this activation enhances tumor cell killing. To test this hypothesis and establish the underlying molecular mechanism, in vitro and in vivo studies were conducted using lung tumor cells that overexpress dominant-negative InBa (dnInBa; H1299-dnInBa) and compared with parental H1299 tumor cells for NF-nB activation and their sensitivity to Ad-mda7 treatment.
Materials and Methods
Cell Lines and Cell Culture Human lung cancer cell lines H1299 (p53 null) and A549 (p53 wild-type) and normal fibroblast cell lines MRC-9 and WI38 were grown and used as described previously (17) . For studies involving H1299 cells that overexpressed dnInBa, tumor cells were stably transfected with 2.5 Ag of a dnInBa plasmid DNA expression vector supplied by one of the authors (P.C.). Cells transfected with a plasmid vector carrying the neomycin gene were used as vector controls. Twenty-four hours after transfection, cells were treated with neomycin (400 Ag/mL) for 14 days to select clones that overexpressed dnInBa. Cells that overexpressed dnInB were labeled as H1299-dnInBa cells and cells transfected with the control neomycin expressing plasmid as H1299-Neo cells. Clones of H1299-dnInBa and H1299-Neo cells were examined for InBa expression by Western blot analysis and compared with parental H1299 cells. These clones were subsequently used in our studies.
Cell Viability Assay Tumor cells (1 Â 10 5 ) were treated with Ad-luc or Admda7 [3,000 viral particles (vp)/cell] and then subjected to a cell viability assay by trypan blue exclusion methods, unless specifically indicated otherwise (17, 18) . For determining the IC 50 , H1299-dnInBa and H1299-Neo cells (1 Â 10 3 ) were seeded in 96-well plates and treated 24 h later with various doses (0, 1,000, 2,000, 3,000, 5,000, and 10,000 vp/cell) of Ad-mda7; 72 h later, the IC 50 value was determined by using a 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner saltbased cell proliferation assay kit (Promega, Madison, WI) according to the manufacturer's instructions. Assays were done in triplicate, and each experiment was conducted at least three separate times to ensure reproducibility.
For experiments involving mitogen-activated protein kinase kinase kinase 1 (MEKK1)-specific small interfering RNA (siRNA), H1299-dnInBa and H1299-Neo cells were first transfected with 200 nmol/L of a MEKK1-specific siRNA or control siRNA (Dharmacon, Inc., Lafayette, CO) by using a LipofectAMINE transfection reagent (Invitrogen, Carlsbad, CA) as described previously (25) . Twentyfour hours after siRNA transfection, cells were treated with Ad-mda7 (3,000 vp/cell); cells were harvested 72 h later, subjected to a cell viability assay by trypan blue exclusion methods, and then analyzed for apoptotic markers by Western blot analysis (17, 18) .
For experiments involving caspase-3 inhibition, H1299-dnInBa and H1299-Neo cells were either treated or not treated with 1 Amol/L of a capase-3 inhibitor (Ac-DEVDcho) or a control inhibitor (Santa Cruz Biotechnology, Santa Cruz, CA) for 24 h. Cells were then treated with PBS or Admda7. All other experimental protocols followed were similar to those described above for MEKK1 siRNA studies.
Immunofluorescence Studies H1299 cells seeded on two-well chamber slides (1 Â 10 5 per well) were treated with PBS, Ad-luc, or Ad-mda7 (3,000 vp/cell) and subjected 24 h later to immunofluorescence analysis. Briefly, cells were fixed in cold methanol for 10 min followed by three washes with PBS, with each wash lasting 3 min. Cells were then incubated with a blocking buffer (Vectastain kit, Vector Laboratories, Burlingame, CA) for 15 min. The blocking buffer was then removed, and the cells were incubated with an anti-human NF-nB antibody (Santa Cruz Biotechnology) for 1 h at room temperature. Cells were then washed thrice with PBS, with each wash lasting 3 min, after which they were incubated with a FITC-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) for 30 min in the dark and then briefly washed with PBS. The slides were mounted on a coverslip with a drop of an antifade product (Molecular Probes, Eugene, OR), observed under a fluorescence microscope (Nikon, Melville, NY), and photographed. Western Blot Analysis H1299, A549, H1299-dnInBa, H1299-Neo, MRC-9, and WI38 cells treated with PBS, Ad-luc, or Ad-mda7 were harvested at appropriate times after treatment and subjected to Western blot analysis (17, 18, 25) . The primary antibodies used were MDA-7 (Introgen Therapeutics, Houston, TX); InBa and NF-nB (Santa Cruz Biotechnology); MEKK1, caspase-3, and poly(ADP-ribose) polymerase (PARP; Cell Signaling Technology, Inc., Danvers, MA); and h-actin (Sigma Chemical Co., St. Louis, MO). The blots were subjected to a semiquantitative analysis as described previously (22, 25) .
Electrophoretic Mobility Shift Assay Cytoplasmic and nuclear extracts from parental H1299 or A549 cells treated with PBS, Ad-luc, or Ad-mda7 (3,000, 5,000, and 10,000 vp/cell) were prepared by harvesting cells at 48 h after treatment (25, 26) . For time course studies, cells were harvested at various time points (i.e., 32, 34, 36, 38, 40, 42, 44, 46, and 48 h) after treatment, and cell extracts were prepared. Extracts were then subjected to electrophoretic mobility shift assay for NF-nB analysis according to the manufacturer's protocol (Promega). The radioactive bands were visualized by a PhosphoImager (Molecular Dynamics, Sunnyvale, CA) and quantitated by using ImageQuant software (Amersham Pharmacia, Piscataway, NJ) as described previously (22, 25) .
To establish that Ad-mda7 -mediated NF-nB activation involves both p65 and p50 subunits of NF-nB, supershift assays were conducted. Briefly, nuclear extracts prepared from cells at 48 h after Ad-mda7 (3,000 vp/cell) treatment were preincubated with anti-p65, anti-p50, anti-p65 plus anti-p50, or anti-cyclin A1 antibody. NF-nB -specific radiolabeled oligonucleotide was subsequently added, and reactions were carried out as described previously (22, 26) .
NF-KB Reporter Assay Parental H1299 cells (5 Â 10
5
) seeded in six-well plates were transfected with a NF-nB-Luc plasmid containing the luciferase gene under the control of the NF-nB promoter (Promega). Cells were transfected with NF-nB-Luc by using FuGENE 6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN; ref. 25) . Three hours after transfection, cells were treated with PBS, empty adenovirus, or Admda7 (3,000 vp/cell). Cells were harvested 48 h later, and luciferase expression was determined as described previously (27) . Luciferase expression was reported as the percentage of increase over the adenovirus control.
In vivo Studies S.c. tumors were established by injecting H1299-Neo or H1299-dnInBa cells (5 Â 10 6 per mouse) into the lower-right flank of nude mice (20 mice for each type of cell). When the tumors were palpable, the animals were divided into two groups for each tumor type (10 mice per group) and treated with intratumoral administration of PBS or Ad-mda7 (5 Â 10 9 vp/dose) thrice weekly until the termination of the experiment. Tumor growth in each group was measured with calipers as described previously (17, 22) . Experiments were done twice, and the tumor size reported was the average mean for each group at each time point. Mice were treated humanely according to our institutional policies.
At the end of the experiment, animals were euthanized by CO 2 inhalation and tumors were excised from all animals, and tumor cell lysates were prepared as described previously (17, 22) . Lysates were checked for MDA-7, MEKK1, NF-nB, InBa, and procaspase-3 expression by Western blot analysis. h-Actin was measured in all Western blots as a loading control.
Statistical Analysis All of the in vitro and in vivo experiments were done at least twice, and the experimental results were analyzed for statistical significance with t tests and ANOVAs. The significance level was set at P < 0.05.
Results

Ad-mda7 Induces NF-KB Expression in Lung Tumor Cells
The treatment of H1299 and A549 tumor cells with Admda7 resulted 48 h later in the activation of NF-nB, which occurred in a dose-dependent manner in both cell types (Fig. 1A) . NF-nB activation was not observed in Ad-luctreated or PBS-treated cells. Associated with Ad-mda7 -mediated NF-nB activation was the increased nuclear accumulation of NF-nB expression compared with that in PBS-treated or Ad-luc -treated H1299 cells (Fig. 1B) . NF-nB activation was associated with the degradation of InB (Fig. 1C) , which also occurred in a dose-dependent manner in both H1299 and A549 tumor cells and with MDA-7 protein expression (Fig. 1C) .
In the supershift assays, anti-p65 and anti-p50 antibody, when added alone or in combination, reduced the intensity of the DNA-binding activity, which suggested that the p50/p65 heterodimer is the activated form of the NF-nB induced by Ad-mda7 (Fig. 1D) . No change in DNA-binding activity was observed when the anti-cyclin A1 antibody was used, which indicated the specificity of the subunits.
Additional evidence for Ad-mda7 -mediated NF-nB activation in tumor cells was provided by measuring the luciferase activity in the H1299 cells that were transiently transfected with a plasmid vector containing the luciferase gene under the control of a NF-nB promoter. The treatment of these transiently transfected cells with Ad-mda7 resulted in a 130% increase in luciferase activity compared with the activity in cells treated with PBS (Fig. 1E) .
To test whether Ad-mda7 induces NF-nB in normal cells, MRC-9 and WI38 fibroblasts were treated with PBS, Ad-luc, or Ad-mda7 (3,000 vp/cell) and analyzed at 48 h after treatment by Western blotting. Analyses of cell lysates showed MDA-7 protein expression in Ad-mda7 -treated cells but not in PBS-treated or Ad-luc -treated cells. However, no significant induction of NF-nB or increased degradation of InB was observed in Ad-mda7 -treated cells compared with PBS-treated or Ad-luc -treated cells (Fig. 1F) . These results showed that Ad-mda7 treatment of lung tumor cells, but not normal cells, results in NF-nB nuclear accumulation, increased DNA binding, and transcriptional activity.
Ad-mda7^Mediated NF-KB Activation Is Time Dependent
To determined at what time NF-nB is activated in Admda7 -treated tumor cells, we next conducted time course experiments in which H1299 cells were treated with Ad-luc or Ad-mda7 at 3,000 vp/cell; nuclear extracts from these cells were prepared at the indicated times and analyzed for DNA-binding activity by electrophoretic mobility shift assay ( Fig. 2A) . Analysis of NF-nB activation showed increased DNA-binding activity from 36 to 48 h in Admda7 -treated cells but not in Ad-luc -treated cells ( Fig. 2A  and B) . The highest DNA-binding activity, however, occurred between 42 and 44 h after Ad-mda7 treatment and decreased thereafter (Fig. 2B) .
Associated with NF-nB activation in Ad-mda7 -treated cells was the marked degradation of InB, which did not occur in PBS-treated or Ad-luc-treated cells (Fig. 2C) . InB degradation at 48 h was associated with robust MDA-7 protein expression. These results showed that Ad-mda7 induced NF-nB activation in tumor cells in a time-dependent manner.
Ad-mda7^Mediated Cell Killing Is Enhanced in dnIKBA-Overexpressing Tumor Cells
The induction of NF-nB by Ad-mda7 indicated that the suppression of this activation would enhance Ad-mda7 -mediated antitumor activity. Therefore, H1299 cells that were stably transfected and overexpressed with either the neo gene (H1299-Neo) or the dnIjBa gene (H1299-dnInB) were analyzed for InBa expression. We found significantly increased InBa expression in two of the three clones (clones 1 and 2) of H1299-dnInBa cells compared with the expression in H1299-Neo cells (Fig. 3A) ; clone 3 showed no significant difference in InBa expression.
After treatment with Ad-mda7, the IC 50 values of clones 1 and 2 of H1299-dnInBa cells were markedly reduced compared with those of H1299-Neo cells (Fig. 3B and C) , with clone 2 being the most sensitive to this treatment.
Clone 3 of H1299-dnInBa cells showed no difference in its IC 50 value compared with that in H1299-Neo cells (Fig. 3B and C). Based on these results, clone 2 was used in all subsequent experiments described below.
To further test whether overexpression of dnInBa sensitizes these cells to Ad-mda7, we treated H1299-dnInBa cells with PBS, Ad-luc, or Ad-mda7 and then compared them with similarly treated H1299-Neo cells. Treatment of both types of cells with Ad-mda7 resulted in a significantly greater inhibition of cell proliferation than occurred in PBS-treated or Ad-luc -treated cells (P < 0.05; Fig. 3D ). However, H1299-dnInBa cells were more sensitive than H1299-Neo cells to Ad-md7 treatment (P < 0.01; Fig. 3D ). A significantly greater growth inhibition was also observed in Ad-luc -treated H1299-dnInBa and H1299-Neo cells than in PBS-treated cells (P < 0.05). We next investigated whether the increased sensitization of H1299-dnInBa to Ad-mda7 was indeed due to suppression of NF-nB activation that is regulated by overexpressing dnInBa. For this purpose, both H1299-Neo and H1299-dnInBa cells were treated with PBS or Ad-mda7. At 48 h after treatment, cell lysates were prepared and analyzed by Western blot analysis. Induction of NF-nB was observed in Ad-mda7 -treated H1299-Neo cells compared with PBS-treated control cells (Fig. 3E) . Associated with NF-nB activation in these cells was the reduction in InB expression levels. In contrast, in H1299-dnInBa cells, the baseline expression levels of NF-nB in PBS-treated cells were less whereas the expression levels of dnInBa were high compared with PBS-treated H1299-Neo cells, indicating NF-nB suppression by dnInBa. Treatment of H1299-dnInBa with Ad-mda7, however, did not result in NF-nB activation but was rather completely suppressed (Fig. 3E) . These results showed that suppression of NF-nB activation by overexpressed dnInBa enhances the antitumor activity of Ad-mda7 in lung tumor cells.
Ad-mda7^Mediated Enhanced Cell Killing in dnIKBAOverexpressing Tumor Cells Involves MEKK1 and Caspase-3
Studies have shown that MEKK1 is upstream of the NFnB/InB pathway and is activated by extracellular signals (28, 29) . Activated MEKK1 phosphorylates InB kinases (IKKa/IKKh), which in turn phosphorylate InB, resulting in its release and degradation from the NF-nB/InB complex, leading to activation of NF-nB. Studies have also shown that MEKK1 is cleaved by a yet unknown mechanism in cells treated with genotoxic agents and that the cleaved MEKK1 enhances apoptosis via caspase-3 activation (30, 31) . Additionally, caspase-3 activation has been shown to lead to increased MEKK1 cleavage (31) . Thus, MEKK1 and caspase-3 interact with each other in a feedback loop, which amplifies the cell death signal and increases cell killing. Based on these reports and our present observation of the increased sensitization of H1299-dnInBa cells to Ad-mda7, we examined MEKK1 and caspase-3 activation in Ad-mda7 -treated H1299-dnnIBa cells and compared it with similar activation in Ad-mda7 -treated H1299-Neo cells.
MEKK1 and caspase-3 activation was observed in Admda7 -treated H1299-dnInBa and H1299-Neo cells on days 2 and 3 after treatment (Fig. 4A ). This activation was markedly higher on both days in Ad-mda7 -treated H1299-dnInBa cells than in Ad-mda7 -treated H1299-Neo cells as indicated by their respective cleavage. The increased MEKK1 and caspase-3 cleavage was associated with increased cleavage of PARP, a substrate for caspase-3, in Ad-mda7 -treated H1299-dnnIBa cells compared with PARP cleavage in Ad-mda7 -treated H1299-Neo cells (Fig. 4A) . No MEKK1, caspase-3, or PARP cleavage was observed in untreated H1299-Neo or H1299-dnInBa cells.
To determine whether MEKK1 or caspase-3 cleavage plays a role in increasing the sensitivity of H1299-dnInBa cells to Ad-mda7, we conducted siRNA experiments. After H1299-Neo and H1299-dnInBa cells were either treated or not treated with MEKK1-specific siRNA or control siRNA for 24 h, they were treated with Ad-mda7 or PBS. H1299-Neo cells treated with Ad-mda7 alone, Ad-mda7 plus control siRNA, or Ad-mda7 plus MEKK1-specific siRNA were markedly growth inhibited (25% inhibition) compared with PBS-treated control cells (P < 0.05; Fig. 4B ). In H1299-dnInBa cells, a substantial growth inhibition was observed in cells treated with Ad-mda7 alone (60% inhibition) and in cells pretreated with control siRNA followed by Ad-mda7 treatment (60% inhibition) compared with PBS-treated cells (P < 0.01; Fig. 4B ). In contrast, Admda7 -mediated growth inhibition was partially abrogated (27% inhibition) when these cells were pretreated with MEKK1-specific siRNA. Thus, MEKK1 seems to play a role for Ad-mda7 function.
MEKK1 cleavage was present in both H1299-Neo and H1299-dnnIBa cells after treatment with Ad-mda7 alone or with control siRNA followed by Ad-mda7 48 h later (Fig. 4C) . MEKK1 cleavage was greater in Ad-mda7-treated H1299-dnnIBa cells compared with Ad-mda7 -treated H1299-Neo cells. However, Ad-mda7-mediated MEKK1 cleavage was inhibited in both cell lines when cells were pretreated with MEKK1-specific siRNA (Fig. 4C) . There was an association between MEKK1 cleavage in cells treated with Ad-mda7 alone or with control siRNA followed by Ad-mda7 and the detection of caspase-3. Increased MEKK1 cleavage observed in Ad-mda7-treated or control siRNA plus Ad-mda7 -treated H1299-dnnIBa cells resulted in increased capase-3 activation that was greater than that observed in Ad-mda7 -treated or control siRNA plus Ad-mda7 -treated H1299-Neo cells. However, when both H1299-Neo and H1299-dnnIBa cells were pretreated with MEKK1-specific siRNA, caspase-3 cleavage was abrogated, which indicated that cleavage of MEKK1 is essential for caspase-3 activation (Fig. 4C) . These findings showed that MEKK1 is highly activated in Admda7 -treated H1299-dnnIBa cells, leading to caspase-3 activation, thereby enhancing the tumor cell killing.
We next examined the effects of inhibiting caspase-3 in Ad-mda7 -treated H1299-Neo and H1229-dnInBa cells. Similar to the MEKK1 siRNA studies, the treatment of H1299-Neo cells with Ad-mda7 alone (28% inhibition), with control inhibitor followed by Ad-mda7 (26% inhibition), or with caspase-3 inhibitor followed by Ad-mda7 (14% inhibition) resulted in significant growth inhibition compared with PBS-treated control cells (P < 0.05; Fig. 4D ). Although inhibition was observed in all treatment, pretreatment with caspase-3 inhibitor markedly reduced Admda7 -mediated inhibition in these cells. In H1229-dnInBa cells treated with Ad-mda7 alone (64% inhibition) or with control siRNA followed by Ad-mda7 (57% inhibition), there was significant growth inhibition compared with PBS-treated control cells, but pretreatment with caspase-3 inhibitor resulted in the loss of this Ad-mda7 -mediated growth-inhibitory effect (17% inhibition; P < 0.05; Fig. 4D ). These findings indicated a requirement for caspase-3 activation to enhance the Ad-mda7 -mediated inhibitory effects.
Studies have previously shown that MEKK1 is a substrate for caspase-3 and is cleaved by caspase-3 (30, 31) . Therefore, to determine whether Ad-mda7 -mediated caspase-3 activation is required for MEKK1 cleavage, studies using caspase-3 inhibitor were again done. In both H1299-Neo and H1229-dnInBa cells, caspase-3 and MEKK1 cleavage was detectable when treated with Ad-mda7 alone or with control siRNA and Ad-mda7 at 48 h after treatment (Fig. 4E) . Caspase-3 and MEKK1 cleavage was greater in H1229-dnInBa cells compared with H1299-Neo cells. However, pretreatment with caspase-3 inhibitor resulted in inhibition of Ad-mda7 -mediated caspase-3 cleavage in both H1299-Neo and H1229-dnInBa cells (Fig. 4E) . There was an association between caspase-3 inhibition and the inhibition of MEKK1 cleavage. These findings showed that Ad-mda7 treatment results in MEKK1 and caspase-3 activation in both H1299-Neo and H1299-dnInBa cells. This activation, however, was increased in H1299-dnInBa cells, which resulted in enhanced sensitivity of these cells to Ad-mda7. Additionally, our results also showed that caspase-3 and MEKK1 are regulated in a feedback loop, in agreement with previous reports (30, 31) . Ad-mda7^Mediated Antitumor Activity Is Enhanced in dnIKBA-Overexpressing Tumors In vivo Treatment of s.c. H1299-Neo or H1299-dnInBa tumors with Ad-mda7 resulted in significantly greater growth inhibition than in PBS-treated tumors for both tumor types (P < 0.05; Fig. 5A ). However, the growth-inhibitory effect was higher in Ad-mda7 -treated H1299-dnInBa tumors (84% inhibition over control) than in Ad-mda7 -treated H1299-Neo tumors (64% inhibition over control) on day 17. The significance of the inhibitory effects in Ad-mda7 -treated H1299-dnInBa tumors continued to increase at later time points (data not shown). However, the growthinhibitory effects beyond day 20 in the two tumor groups could not be compared, as some of the control mice H1299-Neo tumor group were necrotic and the experiment had to be terminated.
To confirm that these increased growth-inhibitory effects were due to activation of the same molecular markers that were observed in vitro, we harvested tumors at the end of the study, prepared tumor cell lysates, and subjected them to Western blot analysis. In Ad-mda7 -treated H1299-Neo tumor cell lysates, MDA-7 protein Figure 4 . Ad-mda7 -mediated enhanced cell killing in dnInBa-overexpressing tumor cells involves MEKK1 and caspase-3. A, analysis for MEKK1, caspase-3, and PARP in Ad-mda7 -treated H1299-Neo and H1299-dnInBa cells at days 1, 2, and 3. The activation of MEKK1 (indicated by MEKK1 cleavage), caspase-3, and PARP was observed on days 2 and 3 in Ad-mda7 -treated H1299-Neo and H1299-dnInBa cells. However, the activation of these molecular markers was higher in H1299-dnInBa cells than in H1299-Neo cells as indicated by the amount of cleaved products. h-Actin was again used as loading control. B, in H1299-dnInBa cells, reduced numbers of cells were observed after treatment with Ad-mda7 alone or with control siRNA followed by Ad-mda7. However, this inhibitory effect was abrogated when cells were pretreated with MEKK1-specific siRNA. In H1299-Neo cells, pretreatment with MEKK1-specific siRNA did not markedly abrogate the Ad-mda7 -mediated inhibitory effect. PBS-treated cells were used as controls in these experiments. C, Western blot analysis of cell lysates from H1299-Neo and H1299-dnInBa cells that were pretreated with control siRNA or MEKK1-specific siRNA followed by Ad-mda7 treatment. The cleavage of MEKK1, albeit at varying expression levels, was observed in both H1299-Neo and H1299-dnInBa cells treated with Ad-mda7 in the presence or absence of control siRNA. However, Ad-mda7 -mediated MEKK1 cleavage was abrogated in cells that were pretreated with MEKK1-specific siRNA. The activation of caspase-3 occurred in Ad-mda7 -treated or Ad-mda7 plus control siRNA -treated cells.
Ad-mda7 -mediated activation of caspase-3 was abrogated in cells that were pretreated with MEKK1-specific siRNA. D, in H1299-dnInBa cells, reduced numbers of cells were observed after treatment with Ad-mda7 alone or with control inhibitor followed by Ad-mda7. However, this Ad-mda7 -mediated inhibitory effect was abrogated when cells were pretreated with a caspase-3 inhibitor. In H1299-Neo cells, pretreatment with a caspase-3 -specific inhibitor slightly abrogated the Ad-mda7 -mediated inhibitory effect but was less than that observed in H1299-dnInBa cells. PBS-treated cells were used as controls in these experiments. E, Western blot analysis of cell lysates from H1299-Neo and H1299-dnInBa cells that were pretreated with the control inhibitor or a caspase-3 inhibitor followed by Ad-mda7 treatment. Caspase-3 and MEKK1 cleavage was observed in cells that were treated with Ad-mda7 in the presence or absence of the control inhibitor. Cleavage of these markers was greater in H1299-dnInBa than in H1299-Neo cells. However, this Admda7 -mediated activation of these markers was abrogated when cells were pretreated with a caspase-3 -specific inhibitor.
expression was observed, which correlated with a decrease in procaspase-3 and a slight increase in MEKK1 cleavage compared with PBS-treated tumors (Fig. 5B) . There was no change in the expression levels of InB between Ad-mda7 -treated and PBS-treated tumors. However, there was increased NF-nB expression in Ad-mda7 -treated tumor compared with PBS-treated tumor, a phenomenon similar to that observed in in vitro studies. In Ad-mda7 -treated tumor cell lysates of H1299-dnInBa tumors, we detected not only MDA-7 protein but also increased MEKK1 cleavage and decreased procapase-3 compared with PBS-treated tumor cell lysates (Fig. 5B) . Additionally, increased InBa expression was observed in both PBS-treated and Ad-mda7 -treated H1299-dnInBa tumors compared with Ad-mda7 -treated H1299-Neo tumors. Associated with increased InBa expression was the suppression of Ad-mda7 -mediated NF-nB induction (Fig. 5B) . Our results thus showed that H1299 tumor cells overexpressing dnInBa are more sensitive to Ad-mda7 in vivo and are due to suppression of NF-nB and activation of MEKK1 and caspase-3.
Discussion
In this study, we investigated whether mda7/IL-24, when overexpressed in lung tumor cells, induces NF-nB expression and whether its suppression enhances mda7/IL-24 -mediated cell killing. We first found that Ad-mda7 treatment of lung tumor cells resulted in NF-nB induction in a dose-dependent manner. NF-nB induction specifically involved the p50/p65 heterodimer as shown by supershift assays. Although the shift using p50 was less than that observed with p65, it is evident that both subunits as a heterodimer participate in Ad-mda7 -mediated NF-nB induction. Furthermore, we found NF-nB induction to occur at about 36 to 48 h after treatment and was attributed to MDA-7 protein expression because a similar level of NF-nB induction was not observed in Ad-luc -treated cells. However, it is to be noted that NF-nB induction was observed in both Ad-luc -treated and Ad-mda7 -treated cells at 24 h after treatment that was attributed to virusmediated induction and attributed as stress response (data not shown). The ability of viral infection to induce NF-nB at less than 24 h is not surprising in light of similar findings in previous reports involving virus-infected cells (32 -34) . Because of this reason and the focus of our study being to test the ability of MDA-7 protein to induce NF-nB, experiments were conducted and analyzed at 48 to 72 h that reflect a role for MDA-7. Additionally, Ad-mda7 induced NF-nB only in tumor cells but not in normal cells.
Whereas this study showed the ability of Ad-mda7 to induce the survival factor NF-nB in lung tumor cells, many studies previously showed that Ad-mda7 also induces potent tumor cell killing (17 -22) . These seemingly contradictory findings are not surprising and can be explained as follows. Tumor cells have an intrinsic cell survival mechanism mediated via NF-nB activation and signaling. However, these cells also have a threshold for survival. When the stress exceeds the threshold, tumor cells proceed toward apoptotic cell death and ultimately die. In fact, tumor cells treated with chemotherapeutic agents, such as etoposide, were shown to initially have increased NF-nB expression that later subsided and was followed by cell death (35) . Similarly, cisplatin treatment of human tumor cell lines was shown to increase activation of IKK, which resulted in InB degradation and NF-nB release (36); cisplatinmediated NF-nB activation was thus shown to be required for tumor cell apoptosis. Treatments with various other therapeutic modalities, such as cytokines and radiation therapy, which induce tumor cell death, were also shown to induce NF-nB in cancer cells (8 -12) . These studies support both our present findings on the ability of Ad-mda7 to induce NF-nB at earlier time points and our previous findings on the ability of Ad-mda7 to induce cell death at later time points. Thus, MDA-7 protein expression in tumor cells results in NF-nB activation as an intrinsic mechanism of tumor cells to resist apoptosis, but sustained protein expression overcomes the cell survival threshold and leads to activation of the apoptotic machinery and cell death.
Our demonstration of the ability of Ad-mda7 to induce NF-nB expression also provided us with a potential way to suppress this expression and thereby enhance Ad-mda7 -mediated antitumor activity. Our findings showing a lowering of the IC 50 values and an increased sensitivity to Ad-mda7 of H1299-dnInBa cells were similar to those of Wang et al. (11) , who showed that the inhibition of NF-nB in chemoresistant tumor cells restored cell sensitivity to the chemotherapeutic drug irinotecan.
We also investigated the underlying molecular mechanism for this increased sensitivity of H1299-dnInBa cells to Ad-mda7. Activation of IKKa has been shown to lead to phosphorylation and degradation of InBa with subsequent NF-nB release into the nucleus, where it acts as a transcriptional activator (28) . Studies have also shown that activation of IKKa is mediated by MEKK1 (28, 29) . According to this line or argument, the activation of MEKK1 should lead to IKKa phosphorylation, InBa degradation, and resultant NF-nB activation, which is implicated in cell survival. These studies established a direct role for MEKK1 in the NF-nB/InB pathway. In addition to MEKK1 playing a role in the NF-nB/InB pathway, studies have also shown that MEKK1 on activation by genotoxic and stress-inducing agents is cleaved by caspase-3 into a 91-kDa fragment and that this fragment promotes apoptosis by activating caspase-3 (30, 31) . Thus, the cleaved MEKK1 and caspase-3 function in an autocrine loop to activate each other and enhance apoptotic cell death. Based on these studies, we speculated by using dnInBa the ability of MEKK1 to promote InBa degradation should be abrogated and facilitate in promoting apoptosis.
We therefore investigated the expression levels of MEKK1 in Ad-mda7 -treated cells. In both H1299-Neo and H1299-dnInBa cells, Ad-mda7 treatment decreased the expression of total MEKK1 compared with untreated cells. Associated with this decrease was the appearance of a cleaved MEKK1 product banding at 91 kDa in Ad-mda7 -treated cells. The amount of the cleaved MEKK1 product was markedly increased in Ad-mda7 -treated H1299-dnInBa cells compared with that in Ad-mda7 -treated H1299-Neo cells. This increased MEKK1 cleavage was associated with increased caspase-3 activation and PARP cleavage. These findings suggested that Ad-mda7 treatment results in MEKK1 cleavage that favors apoptosis as shown by the caspase-3 activation. Furthermore, the overexpression of dnInBa potentiates Ad-mda7 -mediated MEKK1 cleavage, which results in enhanced cell killing. The specificity and requirement of MEKK1 cleavage for Ad-mda7 -mediated enhanced killing were shown by our siRNA studies. Thus, the increased sensitivity of H1299-dnInBa cells to Ad-mda7 was due to increased MEKK1 and caspase-3 activation. Based on our findings, we speculate that Ad-mda7 treatment of tumor cells induces both apoptotic signal, leading to caspase activation and survival signal by activating MEKK1-mediated InB degradation. On inhibition of InB degradation by dnInB, the MEKK1-mediated survival signal is turned to a strong proapoptotic signal that leads to MEKK1 cleavage, which in turn cleaves caspase-3 and vice versa in an autocrine mechanism. What activates MEKK1 in Ad-mda7 -treated cells is currently unknown and warrants further investigation. To our knowledge, the ability of Ad-mda7 to activate MEKK1 and affect tumor cell apoptosis has not been previously reported.
Finally, our in vivo findings paralleling our in vitro findings showed that intratumoral administration of Admda7 to H1299-dnInBa tumor-bearing mice results in greater tumor growth inhibition than in H1299-Neo tumor-bearing mice. Additionally, cleavage of MEKK1 and caspase-3 was greatly increased in Ad-mda7 -treated H1299-dnInBa tumors than in Ad-mda7 -treated H1299-Neo tumors. Thus, the suppression of Ad-mda7 -mediated NF-nB expression by overexpressed dnInBa enhances Admda7 -mediated lung tumor cell death both in vitro and in vivo and involves the activation and cleavage of MEKK1. The findings from this study provide a rationale for testing additional NF-nB inhibitors or other agents that promote MEKK1 cleavage in combination with Ad-mda7. We anticipate that such combination therapies will have an enhanced therapeutic effect and be suitable for translation to the clinic.
